We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals

59 hedge funds and large institutions have $30.5M invested in Actinium Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

66,894% more capital inflows, than outflows

Capital inflows: $19.1M | Capital outflows: $28.6K

850% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 2

500% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 3

40% more funds holding

Funds holding: 42 → 59 (+17)

15.5% more ownership

Funds ownership: 6.44% → 21.94% (+16%)

Holders
59
Holders Change
+17
Holders Change %
+40.48%
% of All Funds
1.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
19
Reduced
2
Closed
3
Calls
$5​K
Puts
–
Net Calls
+$5​K
Net Calls Change
+$6​K

ATNM Hedge Fund Activity: Q2 2020 in Review

59 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2020, worth a combined $30.5M — up 1,373% from $2.07M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ATNM positions and 3 closed out — a net gain of 15 holders — while 19 added to existing stakes and 2 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $9.34M. The largest seller was UBS Group, cutting an estimated $14.6K.

  • 59 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2020, up from 42 in Q1 2020.
  • Funds reported $30.5M of Actinium Pharmaceuticals stock for Q2 2020, up 1,373% quarter-over-quarter.
  • 18 funds opened new Actinium Pharmaceuticals positions in Q2 2020 and 3 closed out, a net change of +15 holders.
  • The largest Actinium Pharmaceuticals buyer in Q2 2020 was Consonance Capital Management, an estimated $9.34M added.
  • The largest Actinium Pharmaceuticals seller in Q2 2020 was UBS Group, an estimated $14.6K sold.

Based on aggregated 13F filings for Q2 2020.